Long‐term follow‐up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia
暂无分享,去创建一个
[1] L. Doyle,et al. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. , 1995, Biochemical pharmacology.
[2] A. Bartolucci,et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] E. Berman,et al. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. , 1992, Blood.
[4] P. Ritch,et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia , 1992 .
[5] Janice Gabrilove,et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia , 1991 .
[6] N. Winick,et al. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. , 1987, Cancer Research.
[7] C. Haanen,et al. Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4‐demethoxydaunomycin , 1986, Clinical pharmacology and therapeutics.
[8] A. Marmont,et al. 4‐Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study , 1985, Cancer.
[9] B. Leyland-Jones,et al. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. , 1985, Cancer research.